Clinical trials: Clostridium Difficile Infections
Clostridium Difficile Infection
Harnessing the Healthy Gut Microbiota to Cure Patients With Recurrent C. Difficile Infection
CDI (Clostridium difficile infection) causes diarrheal illness and can cause colitis which may be fatal. A patient being treated for CDI has a 10-25% chance of developing relapse. Recurrent CDI is on the rise.
- Trial name
- NCT01372943
- Testing
- "synthetic stool" or pure cultures of probiotic intestinal bacteria
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- Queen's University
Clostridium Difficile Infection
Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection
The first line therapy for an initial episode of CDI (Clostridium difficile infection) is 10-14 days of oral vancomycin which is now recommended over metronidazole in the 2018 guidelines from the Association of Medical…
- Trial name
- TAPER-V (NCT04138706)
- Testing
- Vancomycin
- Where
- 12 sites in Canada
- Volunteers
- 263 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Clostridioides Difficile Infection
The Characteristics and Role of Mucosal Microbiome After Treatment of Clostridioides Difficile Infection
This research is being done to study the ability of C. difficile to colonize the colonic mucosa of individuals with no prior history of C. difficile infection.
- Trial name
- NCT04668014
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection
Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease
This is a randomized, double-blind study to assess the safety and efficacy of fidaxomicin compared to vancomycin for decolonization of C. difficile in IBD patients.
- Trial name
- NCT06794944
- Testing
- Vancomycin (POC), Fidaxomicin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Brigham and Women's Hospital
Clostridioides Difficile Infection Recurrence
Changes in Recipients Gut Microbiota After Fecal Microbiota Transplantation
Clostridioides difficile infection (CDI) is the most common cause of nosocomial diarrhea, and the most common health care-associated infectious disease in the United States, accounting for 15% of overall infections, nearly 30.000…
- Trial name
- NCT05739825
- Testing
- FMT from healthy donors
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Clostridium Difficile Infection-associated Diarrhea and Colitis
Efficacy and Safety of Teicoplanin in CDAD
Primary Objective: Explore the efficacy of teicoplanin (100-200 mg administered orally twice a day for 7 to 14 days) in patients with Clostridium difficile infection-associated diarrhea and colitis Secondary Objective: Evaluate…
- Trial name
- NCT04003818
- Testing
- TEICOPLANIN
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sanofi
Cross Infection, Clostridium Difficile Infection
Evaluation of the Cost of a Nosocomial Infection With Clostridium Difficile
Clostridium difficile is the first cause of nosocomial infectious diarrhea, due to its mode of transmission and its resistance in the environment.
- Trial name
- NCT03025672
- Volunteers
- 10,445 people
- Sponsor
- Lille Catholic University
Clostridium Difficile Infection, Vancomycin Resistant Enterococci Infection
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
The goal of this clinical trial is to determine if oral vancomycin can prevent C.diff infection in adults who are critically ill and are at high risk of C.diff infection due to their medical conditions and being in the hospital.
- Trial name
- NCT07221370
- Testing
- Vancomycin 125mg
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- Riverside University Health System Medical Center
Bacterial Infections
Hospital Wide Roll-Out of Antimicrobial Stewardship
Dramatic increases in antibiotic utilization in hospitals continue to drive antibiotic resistance among hospital-acquired pathogens. However, 30-50% of the antibiotic use in hospitals is unnecessary or inappropriate.
- Trial name
- NCT01587937
- Testing
- Antibiotic stewardship audit-and-feedback to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antibiotics
- Where
- Canada
- Volunteers
- 19,220 people
- Sponsor
- Sunnybrook Health Sciences Centre
Clostridium Difficile Infection
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
The study will involve administering a single dose of investigational drug or placebo in ascending dose cohorts. This study is designed to evaluate the safety and tolerability of investigational drug as well as the efficacy of…
- Trial name
- NCT02830542
- Testing
- SER-262
- Where
- 22 sites in United States
- Volunteers
- 96 people
- Sponsor
- Seres Therapeutics, Inc.
Clostridium Infections
Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years
The purpose of this study is to generate safety, reactogenicity (assessment of any expected or unexpected side effect of the vaccine) and immunogenicity (ability to induce an immune response) data for the development of a…
- Trial name
- NCT04026009
- Testing
- C. difficile investigational vaccine based on the F2 antigen (GSK2904545A), C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B
- Where
- Belgium
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Clostridium Difficile Infections
Safety Registry of a Fecal Microbiota Transplant Cohort
Clostridium difficile infection (CDI) is a major cause of infectious diarrhea and the most important cause of nosocomial diarrhea. Recurrent forms are a major problem with this infection.
- Trial name
- COSMIC-FMT (NCT06311006)
- Where
- France
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Clostridium Difficile Infection
Prospective Observational Study of Clostridium Difficile Infection in Asian Pacific Countries
The aim of this study is to conduct an Asia-Pacific, multi-center, prospective observational study to characterize patients with CDI as well as to understand treatment and management of the disease.
- Trial name
- NCT02223715
- Testing
- CDI Pts
- Where
- Japan
- Volunteers
- 600 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Clostridioides Difficile Infection
The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridioides Difficile Infection
The study is being done to identify types of bacteria associated with the lining of the large intestine in people who have recently been diagnosed with C.
- Trial name
- NCT04679324
- Sponsor
- Mayo Clinic